Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000221438

Medchemexpress LLC Migoprotafib (GDC-1971) | 2377352-49-1 | 98.8% | 454.53 g·mol⁻1 | C25H26N8O | 5 MG
SDP

Catalog No. 5000221438
Encompass_Preferred

Migoprotafib (GDC-1971) is an orally bioavailable, allosteric inhibitor of the protein tyrosine phosphatase SHP2 that inhibits the MAPK/ERK signaling pathway and has demonstrated antitumor activity in preclinical models. Supplied as a high-purity research reagent for laboratory studies.

  • Allosteric SHP2 inhibition with demonstrated cellular activity.
  • Inhibits MAPK/ERK signaling relevant to tumor growth.
  • Orally bioavailable in in vivo studies, suitable for pharmacology research.
  • High purity suitable for research applications (98.8%).
  • Available in small-mass quantities for compound screening and dosing studies.

Catalog No. 50-002-21438 Supplier Medchemexpress LLC Supplier No. HY1449035MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Migoprotafib (GDC-1971) is an orally bioavailable, allosteric inhibitor of the protein tyrosine phosphatase SHP2 that inhibits the MAPK/ERK signaling pathway and has demonstrated antitumor activity in preclinical models. Supplied as a high-purity research reagent for laboratory studies.

  • Allosteric SHP2 inhibition with demonstrated cellular activity.
  • Inhibits MAPK/ERK signaling relevant to tumor growth.
  • Orally bioavailable in in vivo studies, suitable for pharmacology research.
  • High purity suitable for research applications (98.8%).
  • Available in small-mass quantities for compound screening and dosing studies.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.